Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)

NCT02290613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Systemic Sclerosis
Pulmonary Hypertension

Interventions

DRUG: Ambrisentan
DRUG: Placebo

Sponsor

Heidelberg University

Collaborators

[object Object]